Literature DB >> 6389344

Oral vaccination of monkeys with an invasive Escherichia coli K-12 hybrid expressing Shigella flexneri 2a somatic antigen.

S B Formal, T L Hale, C Kapfer, J P Cogan, P J Snoy, R Chung, M E Wingfield, B L Elisberg, L S Baron.   

Abstract

A living oral vaccine, designed to protect against Shigella flexneri 2a infections, was constructed by using Escherichia coli K-12 as a carrier strain. The hybrid strain, designated EC104, contained both chromosomal and plasmid genes from S. flexneri donor strains. In addition to expressing the S. flexneri 2a somatic antigen, it had inherited the property of epithelial-cell invasion. After the oral administration to rhesus monkeys, EC104 was isolated from the feces for up to 3 days, but by day 4 all stool cultures were negative. The serum antibody response against S. flexneri 2a somatic antigen was variable, but the vaccine conferred significant protection against an oral challenge with virulent S. flexneri 2a.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6389344      PMCID: PMC261556          DOI: 10.1128/iai.46.2.465-469.1984

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  11 in total

1.  Studies in shigellosis. III. A controlled evaluation of a monovalent Shigella vaccine in a highly endemic environment.

Authors:  A R HIGGINS; T M FLOYD; M A KADER
Journal:  Am J Trop Med Hyg       Date:  1955-03       Impact factor: 2.345

2.  Failure of parenteral vaccines to protect monkeys against experimental shigellosis.

Authors:  S B Formal; R M Maenza; S Austin; E H LaBrec
Journal:  Proc Soc Exp Biol Med       Date:  1967-06

3.  Protection of Monkeys Against Experimental Shigellosis with Attenuated Vaccines.

Authors:  S B Formal; E H Labrec; A Palmer; S Falkow
Journal:  J Bacteriol       Date:  1965-07       Impact factor: 3.490

4.  Positive selection for loss of tetracycline resistance.

Authors:  B R Bochner; H C Huang; G L Schieven; B N Ames
Journal:  J Bacteriol       Date:  1980-08       Impact factor: 3.490

5.  Protection of monkeys against experimental shigellosis with a living attenuated oral polyvalent dysentery vaccine.

Authors:  S B Formal; T H Kent; H C May; A Palmer; S Falkow; E H LaBrec
Journal:  J Bacteriol       Date:  1966-07       Impact factor: 3.490

6.  Fluorescent-antibody and histological study of vaccinated and control monkeys challenged with Shigella flexneri.

Authors:  S B Formal; T H Kent; S Austin; E H Labrec
Journal:  J Bacteriol       Date:  1966-06       Impact factor: 3.490

7.  Studies with a new generation of oral attenuated shigella vaccine: Escherichia coli bearing surface antigens of Shigella flexneri.

Authors:  M M Levine; W E Woodward; S B Formal; P Gemski; H L DuPont; R B Hornick; M J Snyder
Journal:  J Infect Dis       Date:  1977-10       Impact factor: 5.226

8.  Construction of a potential bivalent vaccine strain: introduction of Shigella sonnei form I antigen genes into the galE Salmonella typhi Ty21a typhoid vaccine strain.

Authors:  S B Formal; L S Baron; D J Kopecko; O Washington; C Powell; C A Life
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

9.  Studies on vaccination against bacillary dysentery. 3. Effective oral immunization against Shigella flexneri 2a in a field trial.

Authors:  D M Mel; A L Terzin; L Vuksić
Journal:  Bull World Health Organ       Date:  1965       Impact factor: 9.408

10.  Alterations in the pathogenicity of Escherichia coli K-12 after transfer of plasmid and chromosomal genes from Shigella flexneri.

Authors:  P J Sansonetti; T L Hale; G J Dammin; C Kapfer; H H Collins; S B Formal
Journal:  Infect Immun       Date:  1983-03       Impact factor: 3.441

View more
  20 in total

1.  Antibody responses in the lungs of mice following oral immunization with Salmonella typhimurium aroA and invasive Escherichia coli strains expressing the filamentous hemagglutinin of Bordetella pertussis.

Authors:  C A Guzmán; R M Brownlie; J Kadurugamuwa; M J Walker; K N Timmis
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

2.  Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen.

Authors:  K L Kotloff; D A Herrington; T L Hale; J W Newland; L Van De Verg; J P Cogan; P J Snoy; J C Sadoff; S B Formal; M M Levine
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

3.  Synthetic peptides of Shiga toxin B subunit induce antibodies which neutralize its biological activity.

Authors:  I Harari; A Donohue-Rolfe; G Keusch; R Arnon
Journal:  Infect Immun       Date:  1988-06       Impact factor: 3.441

4.  Oligonucleotide probes for detection and differentiation of Staphylococcus aureus strains containing genes for enterotoxins A, B, and C and toxic shock syndrome toxin 1.

Authors:  R J Neill; G R Fanning; F Delahoz; R Wolff; P Gemski
Journal:  J Clin Microbiol       Date:  1990-07       Impact factor: 5.948

5.  Protective ribosomal preparation from Shigella sonnei as a parenteral candidate vaccine.

Authors:  V I Levenson; T P Egorova; Z P Belkin; V G Fedosova; J L Subbotina; E Z Rukhadze; E K Dzhikidze; Z K Stassilevich
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

6.  Expression of lipopolysaccharide O antigen in Escherichia coli K-12 hybrids containing plasmid and chromosomal genes from Shigella dysenteriae 1.

Authors:  T L Hale; P Guerry; R C Seid; C Kapfer; M E Wingfield; C B Reaves; L S Baron; S B Formal
Journal:  Infect Immun       Date:  1984-11       Impact factor: 3.441

7.  Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains.

Authors:  A B Hartman; C J Powell; C L Schultz; E V Oaks; K H Eckels
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

8.  Identification and antigenic characterization of virulence-associated, plasmid-coded proteins of Shigella spp. and enteroinvasive Escherichia coli.

Authors:  T L Hale; E V Oaks; S B Formal
Journal:  Infect Immun       Date:  1985-12       Impact factor: 3.441

9.  Combined parenteral and oral immunization results in an enhanced mucosal immunoglobulin A response to Shigella flexneri.

Authors:  D F Keren; R A McDonald; J L Carey
Journal:  Infect Immun       Date:  1988-04       Impact factor: 3.441

10.  Development of Shigella sonnei live oral vaccines based on defined rfbInaba deletion mutants of Vibrio cholerae expressing the Shigella serotype D O polysaccharide.

Authors:  D Favre; S J Cryz; J F Viret
Journal:  Infect Immun       Date:  1996-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.